AnaptysBio, Inc. (ANAB) FinancialsANABFinancialAnaptysBio, Inc.

AnaptysBio, Inc. (ANAB) generates its revenue primarily from Royalty Management, which accounts for 100.0% of total sales, equivalent to $25.56M. Understanding this concentration is critical for investors evaluating how ANAB navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, AnaptysBio, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -135.53%, while the net margin is -206.93%. These profitability ratios, combined with a Return on Equity (ROE) of -114.55%, provide a clear picture of how effectively ANAB converts its operational activities into shareholder value.

In the context of the broader market, ANAB competes directly with industry leaders such as ANIP and LKFT. With a market capitalization of $1.73B, it holds a significant position in the sector. When comparing efficiency, ANAB's gross margin of 100.00% stands against ANIP's 54.97% and LKFT's 25.95%. Such benchmarking helps identify whether AnaptysBio, Inc. is trading at a premium or discount relative to its financial performance.

AnaptysBio's recent financial performance shows volatility, with a gross margin consistently at 100% but a net income of -52,884,000 USD in Q1 2026, indicating ongoing losses despite high gross profits.